OncRef

Clinical Trial: NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Status:

RECRUITING

Phase:

Phase 3

Lead Sponsor:Bristol-Myers Squibb
Information Provided By:Bristol-Myers Squibb
Last Update Posted:2026-10-13

Study Overview

Brief Summary

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Official Title

A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (Atigotatug+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Conditions

Extensive-Stage Small Cell Lung Cancer

Intervention / Treatment

  • Biological: BMS-986489 (Atigotatug+Nivolumab)
  • Biological: Atezolizumab
  • Drug: Carboplatin
  • Drug: Etoposide

Other Study ID Numbers

  • CA245-0001
  • 2024-515740-23
  • U1111-1308-1151

Start Date (Actual)

2025-02-25

Primary Completion Date (Estimated)

2027-08-17

Study Completion Date (Estimated)

2031-07-14

Enrollment (Estimated)

530

Study Type

Interventional

Phase

Phase 3